Veracyte Seeks To Raise $400M To Fund Decipher Biosciences Deal

Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.
Veracyte will use proceeds to finance its Decipher Biosciences acquisition announced yesterday and working capital and other general corporate purposes.
Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
Price Action: VCYT closed 13.47% higher at $73.79 on Wednesday.